Life expectancy for people with metastatic or metastasized lung cancer is low. The 5-year survival rate for small cell lung cancer is 3%, and 8% for non-small cell lung cancer (NSCLC). 25-30% of ...

New research delves into the DNA details and chromatin structures that may predict prognosis in early-stage lung ...

Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) ...

Targeted therapy in metastatic non–small cell lung cancer had a 62% survival advantage, with an increase in the mean total cost by 2.45. Immunotherapy had a survival advantage of 48%, with an increase ...

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later.

Dr Erica Mayer of Dana-Farber Cancer Institute and a patient with metastatic breast cancer discuss how oncologists can ease patients beyond panic after a diagnosis of metastatic breast cancer.

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...

Radiographic disappearance of metastases could be a surrogate marker for outcomes among patients treated for metastatic ...